Deleted Journal,
Год журнала:
2024,
Номер
1(2), С. 134 - 149
Опубликована: Дек. 1, 2024
Niclosamide,
an
FDA-approved
anti-parasitic
drug,
has
demonstrated
significant
potential
as
a
repurposed
anti-cancer
agent
due
to
its
ability
interfere
with
multiple
oncogenic
pathways.
However,
clinical
application
been
hindered
by
poor
solubility
and
bioavailability.
Lipid-based
nanocarrier
systems
such
liposomes,
solid
lipid
nanoparticles
(SLNs),
nanostructured
carriers
(NLCs),
nanoemulsions
(LNE),
along
prodrugs,
have
successfully
employed
researchers
overcome
these
limitations
improve
niclosamide’s
pharmacokinetic
profile.
Lipids
are
the
core
organic
compounds
which
serve
foundation
of
advanced
drug
delivery
methods
in
turn
play
critical
role
enhancing
therapeutic
efficacy
through
improving
encapsulate
niclosamide,
protect
it
from
degradation,
facilitate
release,
may
targeted
future.
While
niclosamide
holds
anticancer
multi-pathway
inhibitory
effects,
challenges
associated
bioavailability
rapid
clearance
underscore
need
for
innovative
chemical
modifications
unlock
full
potential.
This
review
aims
present
latest
instances
lipid-based
compile
successful
strategies
be
when
aiming
develop
effective
therapies.
Abstract
Lipid
nanoparticles
(LNPs)
have
emerged
as
a
transformative
platform
for
the
targeted
delivery
of
therapeutic
agents,
revolutionizing
treatment
paradigms
across
spectrum
diseases.
Since
inception
liposomes
in
1960s,
lipid‐based
nanotechnology
has
evolved
to
address
limitations
such
poor
bioavailability,
off‐target
effects,
and
instability,
thereby
enhancing
efficacy
safety
drug
administration.
This
review
highlights
latest
advancements
LNPs
technology,
focusing
on
their
application
cancer
therapy,
gene
infectious
disease
management,
glaucoma,
other
clinical
areas.
Recent
studies
underscore
potential
deliver
messenger
RNA
(mRNA)
small
interfering
(siRNA)
precise
genetic
intervention,
exemplified
by
breakthroughs
interference
CRISPR‐Cas9
genome
editing.
Additionally,
been
successfully
employed
ameliorate
conditions,
demonstrating
versatility
addressing
both
acute
chronic
disorders.
However,
challenges
persist
concerning
large‐scale
manufacturing,
long‐term
stability,
comprehensive
evaluations.
Future
research
must
focus
optimizing
formulations,
exploring
synergistic
combinations
with
existing
therapies,
expanding
scope
treatable
The
integration
into
personalized
medicine
exploration
applications
diseases
represent
promising
avenues
further
investigation.
are
poised
play
an
increasingly
central
role
development
next‐generation
therapeutics.
Frontiers in Veterinary Science,
Год журнала:
2025,
Номер
11
Опубликована: Янв. 3, 2025
This
study
aimed
to
investigate
the
antibacterial
efficacy
of
probiotic-derived
cell-free
supernatants
(CFS)
encapsulated
within
nanostructured
lipid
carriers
(NLCs)
against
multidrug-resistant
Pseudomonas
aeruginosa
and
Staphylococcus
pseudintermedius.
Additionally,
it
identify
specific
bioactive
compounds
that
contribute
reported
properties
by
characterizing
metabolite
substances
present
in
CFS
using
a
metabolomic
analysis
technique.
Eight
strains
lactic
acid
bacteria
including
Lactiplantibacillus
plantarum
(L22F
L25F),
Pediococcus
acidilactici
(P72N,
BF9,
BF
14,
BYF
20
26)
Ligilactobacillus
salivarius
(BF
12)
were
selected
as
probiotic
candidates.
The
inhibitory
activity
their
cell
free
supernatant
was
tested
clinical
P.
S.
pseudintermedius
isolated
from
skin
wounds
dogs
cats.
An
untargeted
approach
based
on
liquid
chromatography-mass
spectrometry
(LC-MS)
identified
potential
metabolites
CFS.
Cell-Free
Supernatants-Nanostructured
Lipid
Carriers
(CFS-NLCs)
developed,
minimum
bactericidal
concentration
(MBC)
analysed.
Despite
strong
nature
pathogens,
displayed
moderate
most
strains.
acidic
CFS,
combined
with
like
Kanzonol
V
1-Hexanol,
likely
contributed
its
effects
pathogenic
bacteria;
notably,
abundant
L22F,
BF12
BYF26
(L22F_CFS,
BF12_CFS
BYF26_CFS),
while
1-Hexanol
particularly
enriched
P72N
(P72N_CFS),
both
effectively
targeting
bacterial
membranes
disrupt
integrity,
leading
death.
Other
beneficial
such
Pyroglutamylleucine,
Trigoneoside
VIII
18-Nor-4(19),8,11,13-abietatetraene
which
are
have
anti-inflammatory,
antimicrobial
antioxidant
activities,
also
detected
CFS-NLCs
maintained
30-60%
dilutions
product
completely
inhibited
growth
pathogen
even
after
three-months
storage
at
room
temperature.
These
findings
suggest
could
be
promising
biotic
therapy
for
treating
hospital
infections
canine
dermatitis
otitis
caused
International Journal of Chemical Reactor Engineering,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 18, 2025
Abstract
In
recent
years,
nanotechnology
has
emerged
as
a
field
of
study
concerned
with
producing
materials
at
the
nanoscale
and
their
usage
for
research
commercial
purposes
like
nanoelectronics,
biomedicals,
energy
storage,
environmental
remediation,
heat
transfer
applications,
etc.
This
review
provides
comprehensive
analysis
nanofluid
synthesis
methods,
specifically
one-step
two-step
approaches,
focus
on
scalability
industrial
feasibility.
The
main
aim
this
article
is
to
provide
quick
reference
researchers
working
nanofluids
applications
in
various
thermal
systems.
development
enhanced
fluids
result
obvious
demand
that
are
more
efficient.
systematically
examines
advancements
nanofluids,
emphasizing
key
factors
influencing
conductivity,
such
nanoparticle
properties,
base
fluids,
concentration,
stability,
dispersion
mechanisms.
Additionally,
explores
integration
exchangers,
internal
combustion
(IC)
engines,
convective
boiling,
renewable
Furthermore,
address
sustainability
potential
ecological
effects
discussion
impact
presented,
highlighting
need
green
methods
life
cycle
assessments.
intends
useful
information
about
optimization
efficient
management
future
